Juniper Biomedical
Juniper Biomedical is dedicated to dramatically improving therapy for patients with pelvic health conditions through innovative, minimally invasive neuromodulation technology. Their mission is to restore human nature by providing safer, less invasive, and more effective treatment options for pelvic health disorders.
Industries
Nr. of Employees
small (1-50)
Juniper Biomedical
UMASS Medical School, 55 Lake Avenue North, Worcester MA 01655
Products
Long‑term battery‑powered implantable micro‑neuromodulator
A small, chronically implantable device engineered to deliver targeted electrical stimulation directly to distal peripheral nerves for treatment of pelvic health conditions; designed for minimally invasive implantation and low energy consumption.
Long‑term battery‑powered implantable micro‑neuromodulator
A small, chronically implantable device engineered to deliver targeted electrical stimulation directly to distal peripheral nerves for treatment of pelvic health conditions; designed for minimally invasive implantation and low energy consumption.
Services
Designing, building and testing implant prototypes and conducting preclinical studies to generate proof‑of‑concept data for pelvic neuromodulation.
Clinical development support including study design input, clinical operations planning, and advisory from experienced clinical leadership.
Designing, building and testing implant prototypes and conducting preclinical studies to generate proof‑of‑concept data for pelvic neuromodulation.
Clinical development support including study design input, clinical operations planning, and advisory from experienced clinical leadership.
Expertise Areas
- Precision neuromodulation
- Implantable medical device development
- Pelvic health therapeutics
- Preclinical study execution
Key Technologies
- Targeted peripheral nerve stimulation
- Micro‑scale battery‑powered implantable devices
- Low‑power stimulation electronics
- Distal nerve coupling interfaces
News & Updates
Juniper Biomedical will participate in the MedTech Strategist Innovation Summit in San Diego, CA from November 19-21, 2024, showcasing its solutions and engaging with stakeholders.
CEO David Constantine presented the company's neuromodulation micro-implant on the Keynote Stage and participated in panels at the MedTech Innovator Grand Prize Finalists.
Juniper Biomedical was selected as one of only 5 finalists in the MedTech Innovator 2024 program, receiving $25,000 and competing for a $350,000 prize.
Dr. Jessica DeLong, MD, FACS, was appointed as the company's Chief Medical Officer, bringing extensive experience in urology and pelvic health.
David Constantine discussed the role of clinicians in development and commercialization at the American Urogynecologic Society's Business Side of Medicine course.
Juniper was accepted into the 2024 MedTech Innovator cohort, the largest accelerator for medical device, digital health, and diagnostics companies.
Juniper Biomedical will participate in the MedTech Strategist Innovation Summit in San Diego, CA from November 19-21, 2024, showcasing its solutions and engaging with stakeholders.
CEO David Constantine presented the company's neuromodulation micro-implant on the Keynote Stage and participated in panels at the MedTech Innovator Grand Prize Finalists.
Juniper Biomedical was selected as one of only 5 finalists in the MedTech Innovator 2024 program, receiving $25,000 and competing for a $350,000 prize.
Dr. Jessica DeLong, MD, FACS, was appointed as the company's Chief Medical Officer, bringing extensive experience in urology and pelvic health.
David Constantine discussed the role of clinicians in development and commercialization at the American Urogynecologic Society's Business Side of Medicine course.
Juniper was accepted into the 2024 MedTech Innovator cohort, the largest accelerator for medical device, digital health, and diagnostics companies.